What Mucos Pharma does

Mucos Pharma (legal entity: MUCOS Pharma GmbH & Co. KG) is a Berlin-based, privately held pharmaceutical company that develops and markets enzyme-based therapeutics under the Wobenzym brand. The company's foundation rests on a proprietary enzyme combination developed in the 1940s that regulates inflammation rather than suppressing symptoms, supporting treatment of swelling, joint pain, arthrosis, soft tissue rheumatism, post-operative swelling, thrombophlebitis, urogenital inflammation, and sports injuries. Its product portfolio spans three categories: prescription-grade pharmaceuticals (Wobenzym, Phlogenzym mono), food supplements (Wobenzym immun with the enzyme combination plus vitamins C, D, E and minerals zinc, selenium), and cosmetics (Wobecare CBD Aktiv Creme). All products are positioned around natural-origin, inflammation-regulating mechanisms that have been marketed for over 50 years.

The company operates a consumer-direct go-to-market in Germany, distributing exclusively through regulated pharmacy channels (local Apotheken and mail-order Versandhandels-Apotheken). Demand generation is driven by content marketing via the consumer portal wobenzym.de (health guides on joint health, immune support, sports recovery) and a professional Fachportal that targets physicians and pharmacists for medical endorsements. The company does not disclose pricing publicly; revenue is generated through one-time product sales at the pharmacy counter.

Mucos Pharma operates as a subsidiary of Dermapharm Holding SE, a publicly listed German pharmaceutical conglomerate that reported €306 million in Q1 revenue with 12% growth in its Branded Pharmaceuticals segment (the segment housing the enzyme franchise). Headcount is reported at 11-50 employees, consistent with a lean branded-pharma franchise within a larger group. Operating geographies are limited to the DACH region (primarily Germany). No recent funding rounds, M&A activity, leadership changes, or partnerships are disclosed.

Name

Mucos Pharma

Legal name

MUCOS Pharma GmbH & Co. KG

Website

https://mucos.de

Company type

Private

Founded year

1970

Operating status

Operating

Headcount range

11–50 employees

Short description

Mucos Pharma is a Berlin-based, privately held subsidiary of Dermapharm Holding SE that manufactures and markets enzyme-based therapeutics under the Wobenzym brand for German adult consumers with inflammation, joint pain, and immune support needs, distributed through pharmacy channels.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

akta.pro secondary industries

Pain Relief & Anti-Inflammatory (Analgesics) (HLAIADAA), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), OTC Pain Relief & Fever (Analgesics, Anti-inflammatory, Topical Pain Relief) (CRADAMAC)

Keywords

• Enzyme therapy pharmaceuticals
• Inflammation treatment medications
• Pharmaceutical manufacturing
• Dietary supplements
• CBD cosmetics

Headquarters

HQ city

Berlin

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Pharmaceutical Product Sales: Revenue generated from sale of enzyme-based pharmaceutical products (Wobenzym, Phlogenzym mono), dietary supplements (Wobenzym immun), and cosmetics (Wobecare CBD cream) through pharmacy distribution channels in Germany.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Mucos Pharma manufactures and sells enzyme-based pharmaceutical products, dietary supplements, and cosmetics under the Wobenzym brand portfolio, distributed primarily through pharmacies in Germany. Its products treat inflammation, swelling, and pain by regulating inflammation through a proprietary enzyme combination developed in the 1940s, addressing conditions such as trauma, thrombophlebitis, urogenital tract inflammation, arthrosis, soft tissue rheumatism, post-operative swelling, and sports injuries, as well as immune system support and topical CBD application.

Product overview

Mucos Pharma operates a multi-category health product portfolio centered on enzyme-based therapeutics. The core offering is the Wobenzym® brand (Arzneimittel/medication), which provides enzyme combination therapy for inflammation-related conditions. Adjacent products include Phlogenzym® mono (acute swelling treatment), Wobenzym® immun (immune support food supplement), and Wobecare® CBD Aktiv Creme (cosmetic). All products focus on natural, inflammation-regulating approaches using enzyme combinations developed over more than 50 years of expertise.

Differentiator

Problem solved

Functional benefit

Brands

• Wobenzym®: Original enzyme product for supporting treatment of inflammation, swelling, or pain as a result of trauma, thrombophlebitis, urogenital tract inflammation, and painful activated arthroses.
• Phlogenzym® mono
• Wobenzym® immun
• Wobecare® CBD Aktiv Creme

Products and services

• Wobenzym

Quantifiable outcome

• Reduces inflammation-related swelling and pain
• +2 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators2 records

Recent moves4 records

Expansion highlights4 records

Broad incumbents

• Haleon (Voltaren, Germany): Global OTC healthcare company whose Voltaren (diclofenac) franchise is the dominant German OTC anti-inflammatory brand. Sets the competitive benchmark Mucos must overcome in pain and inflammation.
• Madaus (now Viatris Germany): Legacy German natural-pharma brand (formerly Madaus) now within Viatris, with historic strength in herbal and natural-origin medicines. Useful comparable for natural-origin German pharma scaling dynamics.
• STADA Arzneimittel AG: Large German specialty and generics pharmaceutical group with extensive OTC portfolio across Europe. Comparable in being Germany-headquartered and pharmacy-distributed, but at far larger scale.
• Bayer AG (Consumer Health): Diversified German pharma/consumer health major with an extensive OTC pain and inflammation portfolio (e.g., Aspirin). Comparable end-therapeutic areas and pharmacy distribution, but vastly larger scale.

Direct peers

• Biologische Heilmittel Heel GmbH: German manufacturer of biological/natural-origin pharmaceuticals positioned for self-medication and practitioner recommendation. Closely comparable to Mucos in its combination-of-natural-actives approach and pharmacy-channel distribution in Germany.
• Repha GmbH Biologische Arzneimittel: German specialty pharma focused on biological and natural-origin medicines, including enzyme and plant-based products distributed through pharmacies. Closely comparable niche positioning to Mucos's enzyme therapy portfolio.
• Pascoe pharmazeutische Präparate GmbH: Mid-sized German manufacturer of natural and homeopathic pharmaceutical preparations sold through pharmacies. Comparable in therapeutic breadth, scale, and reliance on pharmacist recommendation in Germany.
• Klosterfrau Maria Clementine Martin GmbH: German traditional pharma and OTC manufacturer of natural/herbal medicines for pain, cold, and inflammation indications. Comparable in channel (pharmacy), heritage (centuries-old brand), and natural-active positioning.
• Hermes Arzneimittel GmbH: German mid-market pharma with OTC and dietary supplement portfolio distributed via pharmacies. Comparable scale, channel strategy, and product mix around natural and OTC therapies.
• Hevert-Arzneimittel GmbH & Co. KG: German family-owned pharma focused on natural and homeopathic medicines distributed primarily through pharmacies. Comparable niche positioning, similar scale, and parallel OTC/pharmacy GTM in the DACH market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/mucos-pharma

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mucos Pharma